

# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Michael Wolzt

Organisation/Company: N/A

Country: Austria

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical companies and in medical device companies are those listed below:

#### Pharmaceutical company interests

##### 1.1 Employment

No interest declared

##### 1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-01-2019	01-02-2019	BMS	Individual product related	Eliquis	Anticoagulation	
Current	01-12-2012		MSD	Individual product related	Golimumab	Rheumatoid arthritis	
Past	01-07-2019	01-09-2019	Eli Lilly GesmbH	Cross product related/ general (non product related)			Principle of head to head studies
Current	01-12-2020		Galapagos	Individual product related	Filgotinib	RA, CU	
Past	01-12-2018	01-05-2019	Sanofi_Aventis GmbH	Individual product related	Sotagliflozin	Diabetes	
Past	01-02-2019	01-03-2019	Daiichi	Cross product related/ general (non product related)			Polypharmacy and NOAC
Current	01-01-2013		AstraZeneca	Cross product related/ general (non product related)			Member, Pharmacology Advisory Board
Past	01-02-2015	01-05-2019	Celgene	Individual product related	Apremilast	Psoriatic arthritis	
Current	01-09-2020		Turgut Pharmaceuticals	Cross product related/ general (non product related)			Biosimilar development

##### 1.3 Strategic advisory role

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-09-2017	01-08-2023	AOP	Individual product related	Landiolol	Tachyarrhythmia (pediatric)	

## 1.4 Financial interests

No interest declared

## 1.5 Principal investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-09-2019		BlueSky GmbH	FluBHPVE6E7	HPV_16 infection
Current	01-10-2020		reMYND N.V.	REM0046127	Dementia
Past	01-02-2019	01-11-2020	NeuroKine Therapeutics LLC	MW150	Alzheimer's disease
Past	01-10-2020	06-09-2022	Vertanical GmbH	VER_01	Tetrahydrocannabinol phase 1 studies
Past	01-09-2019	03-05-2022	Megainpharm GmbH	Myramistin	Acute pharyngitis
Past	01-02-2018	01-05-2019	Forschungszentrum Jülich GmbH	Contraloid acetate	Alzheimer's disease

## 1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-06-2020		ReMynd	REM0046127	Alzheimer disease
Past	01-01-2015	01-03-2016	AOP Orphan	Landiolol	Supraventricular tachycardia
Past	01-05-2018	19-01-2023	Viravaxx GmbH	VVX001	Hepatitis B infection
Current	12-12-2023		AstraZeneca	AZD9550	Type 2 Diabetes Mellitus
Past	01-07-2017	28-07-2022	Sanofi_Genzyme	NeoGAA (GZ402666)	Pompe disease

## 1.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
AstraZeneca	Drug utilisation after ACS in AUT

## 1.8 Close family member interest

No interest declared

## 1.9 Repurposing of a medicinal product

No interest declared

## 1.10 Any other interests or facts

Member Ethics Committee Medical University of Vienna, AUT (\_2014)  
Director, Clinical Trials Coordination Centre of the Medical University of Vienna, AUT  
Conference / Seminar attendance and lectures for different companies and not\_for profit organisations

## 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## Medical device company interests

### 2.1 Employment

No interest declared

## 2.2 Consultancy

No interest declared

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

Time Period	Start Date	End Date	Name of medical device company	Product Name	Medical indication/intended purpose
Past	19-02-2019	16-03-2022	Glock Health Science and Research GmbH	Clinoptilolite tuff	Adsorption intestinal and wound fluid

## 2.6 Investigator

No interest declared

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my

work in connection with EMA activities.

- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name:	Michael Wolzt
Date:	2024-02-01

For definitions of activities etc, refer to the policy on handling of competing interests.